產(chǎn)品詳情
簡單介紹：
Anti-LGI2抗體產(chǎn)品質(zhì)量穩(wěn)定，實(shí)驗(yàn)效果明顯，貨期快，價(jià)格優(yōu)惠，歡迎垂詢訂購！我公司長期供應(yīng)**組化抗體、WB抗體、**組化試劑盒和抗體試驗(yàn)所需全部相關(guān)試劑、熒光標(biāo)記抗體、單克隆抗體、多克隆抗體、各種標(biāo)記的二抗IgG/IgM/IgD/IgA等科研實(shí)驗(yàn)抗體。Anti-LGI2抗體用于**組化實(shí)驗(yàn),WB實(shí)驗(yàn),相應(yīng)的標(biāo)記抗體有HRP標(biāo)記抗體,FITC標(biāo)記,BIO等。
詳情介紹：
Rabbit Anti-LGI2
Cat. Number:
Anti-LGI2抗體KL-18235R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
The leucine-rich (LRR) repeat is a 20-30 amino acid motif that forms a hydrophobic Alpha/Beta horseshoe fold, allowing it to accommodate several leucine residues within a tightly packed core. All LRR repeats contain a Anti-LGI2抗體variable segment and a highly conserved segment, the latter of which accounts for 11 or 12 residues of the entire LRR motif. LGI2 (leucine-rich repeat LGI family, member 2), also known as KIAA1916 or LGIL2, is a 545 amino acid secreted protein that contains four LRR repeats and seven EAR repeats. Expressed in heart, brain and placenta, LGI2 shares high sequence similarity with other LGI family members and is thought to play a role in the pathogenesis of epileptic disorders.
Also known as:
KIAA1916; Leucine rich glioma inactivated protein 2; Leucine rich repeat LGI family member 2; Leucine-rich glioma-inactivated protein 2; Anti-LGI2抗體Leucine-rich repeat LGI family member 2; LGI1 like protein 2; LGI1-like protein 2; LGI2; LGI2_HUMAN; LGIL2.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Chicken, Pig, Cow, Horse, Sheep, Guinea Pig, .
●
Immunogen: KLH conjugated Anti-LGI2抗體synthetic peptide derived from human LGI2.
●
Predicted Molecular Weight: 60kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500
Not yet tested in other applications. Anti-LGI2抗體
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications. Anti-LGI2抗體
Optimal working dilutions must be determined by the end user.
